Prima BioMed Announces Two Accepted Abstracts for Presentation at ISCT Annual Meeting

Prima BioMed Announces Two Accepted Abstracts for Presentation at ISCT Annual 
SYDNEY, AUSTRALIA -- (Marketwire) -- 02/03/13 --  Prima BioMed Ltd
(ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", "the
Company") announces that two abstracts related to research and
development of CVac(TM) have been accepted by the International
Society for Cellular Therapy (ISCT) for presentation at its 19th
annual meeting in Auckland, New Zealand from 22-25 April 2013.  
The two poster presentations are; 

--  "Qualification of an intracellular cytokine staining (ICS) assay to
    evaluate mucin 1-specific T cell responses in ovarian cancer patients
    treated with CVac(TM) immunotherapy" by Dr. Sharron Gargosky et al.;
--  "Qualification of the COSTIM assay to determine potency and use in
    clinical trials" by Dr. Michael Buchholtz et al.

Dr. Gargosky's poster will describe the use of intracellular cytokine
staining (ICS) assays to measure mucin 1-specific T cells in
patient's peripheral blood mononuclear cells (PBMC). Dr. Buchholtz's
poster will describe the process of developing and qualifying the
COSTIM assay to assess the potency of a product like CVac(TM).  
Both posters will be presented during the Immunotherapy, Regenerative
Medicine, Translational Process Development and Gene Therapy session
on Wednesday, 24 April 2013 from 5:00pm to 6:30pm. 
About Prima BioMed
 Prima BioMed is a globally active biotechnology
company. As a leader in personalized bio-therapeutic products for
cancer, Prima is dedicated to leveraging its current technology and
expertise to develop innovative treatment options for patients and to
maximize value to shareholders. Prima's lead product is CVac(TM), an
autologous dendritic cell product currently in clinical trials for
ovarian cancer patients who are in remission. 
For further information please contact: 
USA Investor/Media:
Ms. Jessica Brown
Prima BioMed Ltd. 
+1 (919) 710-9061  
Australia Investor/Media:
Mr. James Moses
Mandate Corporate 
+61 (0) 420 991 574  
Europe Investor/Media:
Mr. Axel Muhlhaus
edicto GmbH
+49 (0) 69 905505-52 
Press spacebar to pause and continue. Press esc to stop.